Please login to the form below
Intellectual property
This page shows the latest Intellectual property news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn
Under the terms of the agreement, Novo Nordisk will gain full worldwide rights to the intellectual property and related rights to Prothena’s ATTR amyloidosis business and pipeline.
Latest news
-
Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’
Pfizer has cautioned against removing intellectual property (IP) protections in a submission to an Australian parliamentary inquiry into vaccine fraud. ... premise that their intellectual property will be protected,” he added.
-
Pfizer, BioNTech file for full US approval of COVID-19 vaccine
In an open letter to Pfizer employees, Bourla also responded to the news that the US is supporting a proposal to waive intellectual property (IP) protections on COVID-19 vaccines.
-
US backs proposal to waive IP protection for COVID-19 vaccines
The US has announced that it will support a proposal to waive intellectual property (IP) and patents on all COVID-19 vaccines, aiming to “get as many safe and effective vaccines
-
Bayer strengthens cell and gene therapy focus with new platform
Bayer paid an initial $2bn to gain full rights to AskBio’s gene therapy platform, which included an intellectual property portfolio and an established contract development and manufacturing organisation (CDMO).
-
Sobi’s Gamifant receives final rejection from CHMP for primary HLH
Sobi, based in Stockholm, Sweden, acquired the global marketing rights to Gamifant from Novimmune in July 2018, and in June 2019 the company spent $518m to acquire the outstanding intellectual property
More from news
Approximately 4 fully matching, plus 292 partially matching documents found.
Latest Intelligence
-
Integrating competitive intelligence into business development, licensing and M&A strategy
including research, clinical development, regulatory, intellectual property, market research and commercial assessment.
-
How can virtual pharma companies de-risk new product launches?
affairs. They also need access to broader business knowledge spanning financials, tax, legal, intellectual property tactics and commercial strategy.
-
Rethinking our approach to infectious disease preparedness
Deals keep the wheels of R&D turning, allowing early stage seed investors to get their money back when another business acquires that intellectual property or buys the company.
-
A snapshot of… Enterprise Therapeutics
However, the short-term uncertainty caused by Brexit makes planning more difficult and therefore introduces perceived risks in terms of costs, access to markets, protection of intellectual property and access to
-
Shanks v Unilever? Or David v Goliath?
He therefore launched an application for compensation in the United Kingdom Intellectual Property Office.
More from intelligence
Approximately 2 fully matching, plus 42 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Andrade mostly comes from a business development, management and intellectual property background within pharmaceutical and biotech,.
-
Tony de Fougerolles joins Evox Therapeutics as CEO
the company’s intellectual property estate.
-
IFPMA appoints Fumie Griego as assistant director general
and background in global affairs, including intellectual property protection, pricing, costs, value issues and health diplomacy.
-
Robocath appoints CEO
He will now oversee the clinical development and rollout of the R-One robot, as well as work to consolidate the firm's intellectual property and assets.
-
Chase adds former Allergan execs to leadership team
With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease.
More from appointments
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest from PMHub
-
Blockchain for Tracking and Validating Medical Cannabis
Robert Galarza, CEO of TruTrace Technologies, Inc., dives into the use of blockchain technology for verifying medical cannabis products and protecting intellectual property.
-
It's out - so what?
intellectual property system for pharmaceuticals, setting up a new authority for health emergency response, strengthening security of supply in the EU, launching a group to steer cooperation between national authorities on
-
EU Pharmaceutical Strategy Roadmap
This includes making sure the EU creates the right environment for innovation by retaining incentives for industry and creating a competitive intellectual property framework.
-
Designing a global digital patient services platform
There was a variety of pre-existing service design capabilities, initiatives and intellectual property, but many were hidden from the local markets.
-
Tapping the potential of rare diseases: A journey into uncharted territory
intellectual property protection.
EU Pharmaceutical Strategy Roadmap
More from PMHub
Approximately 1 fully matching, plus 13 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- bluebird bio’s beti-cel accepted for priority review by FDA
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
- Onyx Health Announces Two Top Appointments
- Omicron prompts global action
- Novo Nordisk growth takes a hit with China deal
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Six ways to improve diversity in clinical trials
- Innovation in a digital context is not about technology – it’s about people
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Novartis forms coronavirus alliance with life sciences companies
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
